Vaxcyte Inc

$30.65
(as of Apr 17, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Vaxcyte Inc

Stock Price
$30.65
Ticker Symbol
PCVX
Exchange
NASDAQ

Industry Information for Vaxcyte Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Vaxcyte Inc

Website
https://vaxcyte.com
Country
USA
Full Time Employees
414

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Fundamentals for Vaxcyte Inc

Market Capitalization
$3,946,555,136
EBITDA
$-562,542,976
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-3.80
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
128,762,000
Percent Owned by Insiders
0.50%
Percent Owned by Institutions
111.97%
52-Week High
52-Week Low

Technical Indicators for Vaxcyte Inc

50-Day Moving Average
200-Day Moving Average
RSI
26.64
ATR
4.28

Analyst Ratings for Vaxcyte Inc

Strong Buy
9
Buy
2
Hold
0
Sell
0
Strong Sell
0

News About Vaxcyte Inc

Apr 16, 2025, 7:53 AM EST
We can readily understand why investors are attracted to unprofitable companies. See more.
Apr 11, 2025, 4:21 PM EST
We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. See more.
Apr 10, 2025, 1:07 PM EST
Vaxcyte PCVX is a clinical-stage biotech focused on developing vaccines to prevent or treat bacterial infectious diseases. See more.
Apr 1, 2025, 12:45 PM EST
Evercore ISI notes that Vaxcyte (PCVX) missed four serotypes versus Prevnar20 in the “all-important” infant data, adding that an “imperfect vaccine press release on the heels of Peter Marks resignation is just tough timing.” See more.